Glucose-Responsive Insulin
Type 1 and Type 2 Diabetes
PreclinicalActive
Key Facts
About Sensulin
Sensulin is a private, preclinical-stage biotech based in San Diego, pioneering a next-generation, glucose-responsive insulin. Founded in 2013, the company leverages a proprietary drug delivery platform to create an insulin that activates in response to high blood sugar and deactivates when glucose normalizes, targeting a fundamental limitation of current insulin therapy. With a seasoned leadership team experienced in diabetes drug development and company building, Sensulin is positioned to address a massive market opportunity if its technology successfully translates through clinical development. The company faces significant technical and competitive risks inherent to its ambitious, platform-defining program.
View full company profileTherapeutic Areas
Other Type 1 and Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| iPSC-Derived Islet Cell Therapy | Regenerative Medical Solutions | Clinical Trials (phase unspecified) |
| Diabetes Clinical Trials | Diablo Clinical Research | Phase 1-3 |